How Oppositionality, Inattention, and Hyperactivity Affect Response to Atomoxetine Versus Methylphenidate: A Pooled Meta-Analysis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective: To assess how threshold oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity affect the response to atomoxetine versus methylphenidate. Method: Systematic review of randomized controlled trials (RCTs; ≥6 weeks follow-up). The primary measure was core symptom response—≥40% reduction in ADHD Rating Scale-IV–Parent Version: investigator administered and scored total or domain subscores, as appropriate. Results: Data from 1,391 children and adolescents (823 atomoxetine, 568 methylphenidate; 7 RCTs) were meta-analyzed. The mean difference in response rates for patients with ODD was 0.6% (95% confidence interval [CI] = −11.9%-13.1%). The “without ODD” patient group showed significant between-trial heterogeneity ( p < .001). Response rate differences for patients meeting the threshold for inattention or hyperactivity-impulsivity were −3.1% (95% CI = −11.5%-5.3%) and −4.9% (95% CI = −14.3%-4.4%), respectively. Conclusions: Meeting the threshold criteria for oppositionality, inattention, or hyperactivity-impulsivity did not alter core ADHD symptom response to atomoxetine versus methylphenidate, which was equivalent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · cited 2×
“…with a meta-analysis of data from three randomized placebocontrolled trials assessing the reduction in ADHD symptoms in response to atomoxetine (Biederman et al., 2007) and with studies from the multimodal treatment study of children with ADHD (Jensen et al., 2001; The MTA Cooperative Group, 1999).”
BackgroundMethodGreenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1088 · Cited by 652
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“…trial data showing that, although the onset of action of atomoxetine occurs within 1 to 3 weeks, the response to treatment continues to increase from 3 weeks and a minimum of 4 to 6 weeks is required to evaluate response to treatment (Michelson et al., 2002; Newcorn, Sutton, Weiss, & Sumner, 2009).”
BackgroundThe Challenge of Subgroup Analyses — Reporting without Distorting
Lagakos, S. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068070 · Cited by 504 · cited 2×
“The advantage of this approach is that CIs provide a plausible range for the true difference between treatment groups and minimize the overinterpretation of findings that can occur when multiple analyses are conducted (Lagakos, 2006).”
BackgroundPelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378 · cited 1×
“All osmotic release oral system (OROS) methylphenidate doses were converted to the immediate release (IR) equivalent for this analysis (Pelham et al., 2001).”
MethodSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 8×
“The percentage of patients with comorbid ODD in each trial was 61.7% (111/180; Prasad et al., 2007), 53.6% (45/84; Spencer et al., 2002), 51.6% (112/217; Kratochvil et al., 2002), 47.6% (39/82; Sangal et al., 2006), 44.2% Table 1.”
BackgroundMethodInfluentialBiederman, J., Petty, C. R., Dolan, C., Hughes, S., Mick, E., Monuteaux, M. C., & Faraone, S. V. (2008) · Psychological Medicine · doi:10.1017/s0033291707002668 · Cited by 299
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · cited 8×
“The percentage of patients with comorbid ODD in each trial was 61.7% (111/180; Prasad et al., 2007), 53.6% (45/84; Spencer et al., 2002), 51.6% (112/217; Kratochvil et al., 2002), 47.6% (39/82; Sangal et al., 2006), 44.2% Table 1.”
BackgroundResultInfluentialEffects of Atomoxetine and Methylphenidate on Sleep in Children With ADHD
Sangal, R. B., Owens, J., Allen, A. J., Sutton, V., Schuh, K., & Kelsey, D. (2006) · Sleep · doi:10.1093/sleep/29.12.1573 · Cited by 214 · cited 10×
“The percentage of patients with comorbid ODD in each trial was 61.7% (111/180; Prasad et al., 2007), 53.6% (45/84; Spencer et al., 2002), 51.6% (112/217; Kratochvil et al., 2002), 47.6% (39/82; Sangal et al., 2006), 44.2% Table 1.”
BackgroundMethodInfluentialCheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185 · cited 1×
“…that assessed potential study, participant, and study quality factors associated with ADHD treatment efficacy, the participant characteristics of comorbid ODD, ADHD hyperactivity-impulsivity subtype, and male gender were associated with smaller reductions in ADHD symptoms (Cheng et al., 2007).”
BackgroundKRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000222788.34229.68 · Cited by 150 · cited 1×
“Atomoxetine is a well-tolerated, nonstimulant medication that has proven efficacy in reducing core ADHD symptoms in children and adolescents (Kratochvil et al., 2006; Wilens et al., 2006).”
BackgroundLong-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., Feldman, P. D., & Levine, L. R. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.052 · Cited by 102 · cited 1×
“Atomoxetine is a well-tolerated, nonstimulant medication that has proven efficacy in reducing core ADHD symptoms in children and adolescents (Kratochvil et al., 2006; Wilens et al., 2006).”
BackgroundKemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99 · cited 3×
“The publications excluded for not meeting the 6-week follow-up criterion described a 3-week, randomized, controlled, open-label trial (Kemner et al., 2005), and a subgroup analysis of African American participants from the same trial (Starr & Kemner, 2005).”
BackgroundPrasad, S., Harpin, V., Poole, L., Zeitlin, H., Jamdar, S., Puvanendran, K., & on behalf of the SUNBEAM Study Group (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167309 · Cited by 97 · cited 8×
“The percentage of patients with comorbid ODD in each trial was 61.7% (111/180; Prasad et al., 2007), 53.6% (45/84; Spencer et al., 2002), 51.6% (112/217; Kratochvil et al., 2002), 47.6% (39/82; Sangal et al., 2006), 44.2% Table 1.”
BackgroundInfluentialNewcorn, J. H., Sutton, V. K., Weiss, M. D., & Sumner, C. R. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c55b2 · Cited by 92
Wang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84 · cited 8×
“Wang et al. (2007) LYBR (23) Multicenter, doubleblind, randomized, and parallel 6-16 162 ATX 20-80 QD 8 No 38 (23.5”
BackgroundInfluential
Cited by
Cubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M. J., Simmons, A., & Rubia, K. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs296 · Cited by 116
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“Co-morbid conditions 43 [17–21, 52, 60, 78, 87, 101, 102, 104, 115, 117–119, 129, 137, 138, 140–153, 155–164]”
BackgroundBari, A., & Robbins, T. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3141-6 · Cited by 105
“Both have comparable efficacy in ADHD (Hazell et al. 2011; van Wyk et al. 2012), although psychostimulants remain widely used for this purpose (Wilens 2008).”
BackgroundPharmacogenetics predictors of methylphenidate efficacy in childhood ADHD
Myer, N. M., Boland, J. R., & Faraone, S. V. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.234 · Cited by 91
The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis
De Crescenzo, F., Armando, M., Mazzone, L., Ciliberto, M., Sciannamea, M., Figueroa, C., Janiri, L., Quested, D., & Vicari, S. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0122-x · Cited by 48
Metadata
- Authors
- van Wyk, G. W., Hazell, P. L., Kohn, M. R., Granger, R. E., & Walton, R. J.
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2011-02-02
- Volume
- 16
- Issue
- 4
- Pages
- 314-324
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2066273571
- Cited by
- 20
- References
- 18
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.